Acadia Pharmaceuticals Submits New FDA For Parkinson's Psychosis Drug

Acadia Pharmaceuticals said Thursday it has submitted a New Drug Application to the U.S. Food and Drug Administration for its Nuplazid treatment for psychosis associated with Parkinson's Disease. "NUPLAZID holds promise for patients with Parkinson's disease psychosis who currently have no FDA-approved treatment options," said Steve Davis, who was named Chief Executive of Acadia in a separate statement early Thursday. Davis joined the company in July 2014 as chief financial officer, and became interim CEO in March. He has previously worked at Heron Therapeutics, Ardea Biosciences Inc. and at Neurogen, said the statement. About one million people in the U.S. suffer from Parkinson's, according to the National Parkinson Foundation. Acadia shares were indicating higher in light, premarket trade, but are up 20% in the year so far, while the S&P 500 has lost 5.3%.